Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Immunology and Cancer Research: Baniyash Michal


Last updated December 2021 -  Immunology and Cancer Research

List of Publications

(1) Luo L, Liang W, Pang J, Xu G, Chen Y, Guo X, et al. Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals. Cell Discov 2021;7(1).

(2) Ashkenazi-Preiser H, Mikula I, Baniyash M. The diverse roles of myeloid derived suppressor cells in mucosal immunity. Cell Immunol 2021;365.

(3) Maimon A, Levi-Yahid V, Ben-Meir K, Halpern A, Talmi Z, Priya S, et al. Myeloid cell–derived PROS1 inhibits tumor metastasis by regulating inflammatory and immune responses via IL-10. J Clin Invest 2021;131(10).

(4) Ben-Meir K, Twaik N, Baniyash M. Plasticity and biological diversity of myeloid derived suppressor cells. Curr Opin Immunol 2018;51:154-161.

(5) Mizrahi O, Ish Shalom E, Baniyash M, Klieger Y. Quantitative Flow Cytometry: Concerns and Recommendations in Clinic and Research. Cytometry Part B Clin Cytometry 2018;94(2):211-218.

(6) Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun 2017;8(1).

(7) Meirow Y, Baniyash M. Immune biomarkers for chronic inflammation related complications in non-cancerous and cancerous diseases. Cancer Immunol Immunother 2017;66(8):1089-1101.

(8) Sade-Feldman M, Kanterman J, Klieger Y, Ish-Shalom E, Olga M, Saragovi A, et al. Clinical significance of circulating CD33+ CD11bHLA-DR myeloid cells in patients with stage IV melanoma treated with ipilimumab. Clin Cancer Res 2016;22(23):5661-5672.

(9) Baniyash M. Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy. Cancer Immunol Immunother 2016;65(7):857-867.

(10) Tarcic O, Pateras IS, Cooks T, Shema E, Kanterman J, Ashkenazi H, et al. RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer. Cell Rep 2016;14(6):1462-1476.

(11) Ish-Shalom E, Meirow Y, Sade-Feldman M, Kanterman J, Wang L, Mizrahi O, et al. Impaired SNX9 expression in immune cells during chronic inflammation: Prognostic and diagnostic implications. J Immunol 2016;196(1):156-167.

(12) Meirow Y, Kanterman J, Baniyash M. Paving the road to tumor development and spreading: Myeloid-derived suppressor cells are ruling the fate. Front Immunol 2015;6(OCT).

(13) Eldor R, Klieger Y, Sade-Feldman M, Vaknin I, Varfolomeev I, Fuchs C, et al. CD247, a novel T cell-derived diagnostic and prognostic biomarker for detecting disease progression and severity in patients with type 2 diabetes. Diabetes Care 2015;38(1):113-118.

(14) Hefetz-Sela S, Stein I, Klieger Y, Porat R, Sade-Feldman M, Zreik F, et al. Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation. Proc Natl Acad Sci U S A 2014;111(49):17582-17587.

(15) Kanterman J, Sade-Feldman M, Biton M, Ish-Shalom E, Lasry A, Goldshtein A, et al. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res 2014;74(21):6022-6035.

(16) Klieger Y, Almogi-Hazan O, Ish-Shalom E, Pato A, Pauker MH, Barda-Saad M, et al. Unique ζ-chain motifs mediate a direct TCR-actin linkage critical for immunological synapse formation and T-cell activation. Eur J Immunol 2014;44(1):58-68.

(17) Baniyash M, Sade-Feldman M, Kanterman J. Chronic inflammation and cancer: Suppressing the suppressors. Cancer Immunol Immunother 2014;63(1):11-20.

(18) Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M. Tumor Necrosis Factor-α Blocks Differentiation and Enhances Suppressive Activity of Immature Myeloid Cells during Chronic Inflammation. Immunity 2013;38(3):541-554.

(19) Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L, et al. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol 2013;133(6):1610-1619.

(20) Kanterman J, Sade-Feldman M, Baniyash M. New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol 2012;22(4):307-318.

(21) Meyera C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osena W, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A 2011;108(41):17111-17116.

(22) Silberman I, Sionov RV, Zuckerman V, Haupt S, Goldberg Z, Strasser A, et al. T cell survival and function requires the c-Abl tyrosine kinase. Cell Cycle 2008;7(24):3847-3857.

(23) Fainstein N, Vaknin I, Einstein O, Zisman P, Sasson SZB, Baniyash M, et al. Neural precursor cells inhibit multiple inflammatory signals. Mol Cell Neurosci 2008;39(3):335-341.

(24) Vaknin I, Blinder L, Wang L, Gazit R, Shapira E, Genina O, et al. A common pathway mediated through Toll-like receptors leads to T- and natural killer-cell immunosuppression. Blood 2008;111(3):1437-1447.

(25) Marhaba R, Vitacolonna M, Hildebrand D, Baniyash M, Freyschmidt-Paul P, Zöller M. The importance of myeloid-derived suppressor cells in the regulation of autoimmune effector cells by a chronic contact eczema. J Immunol 2007;179(8):5071-5081.

(26) Einstein O, Fainstein N, Vaknin I, Mizrachi-Kol R, Reihartz E, Grigoriadis N, et al. Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. Ann Neurol 2007;61(3):209-218.

(27) Ezernitchi AV, Vaknin I, Cohen-Daniel L, Levy O, Manaster E, Halabi A, et al. TCR ζ down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol 2006;177(7):4763-4772.

(28) Baniyash M. The inflammation-cancer linkage: A double-edged sword? Semin Cancer Biol 2006;16(1):1-2.

(29) Baniyash M. Chronic inflammation, immunosuppression and cancer: New insights and outlook. Semin Cancer Biol 2006;16(1):80-88.

(30) Baniyash M. TCR ζ-chain downregulation: Curtailing an excessive inflammatory immune response. Nat Rev Immunol 2004;4(9):675-687.

(31) Bronstein-Sitton N, Cohen-Daniel L, Vaknin I, Ezernitchi AV, Leshem B, Halabi A, et al. Sustained exposure to bacterial antigen induces interferon-γ-dependent T cell receptor ζ down-regulation and impaired T cell function. Nat Immunol 2003;4(10):957-964.

(32) Gonen-Gross T, Achdout H, Gazit R, Hanna J, Mizrahi S, Markel G, et al. Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol 2003;171(3):1343-1351.

(33) Caplan S, Baniyash M. Radioiodination of cellular proteins. Curr Protoc Cell Biol 2002;Chapter 7.

(34) Caplan S, Almogi-Hazan O, Ezernitchi A, Manaster E, Gazit A, Baniyash M. The cytoskeleton-associated TCR ζ chain is constitutively phosphorylated in the absence of an active p56lck form. Eur J Immunol 2001;31(2):580-589.

(35) Villa A, Sobacchi C, Notarangelo LD, Bozzi F, Abinun M, Abrahamsen TG, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: Severe immunodeficiency with a spectrum of clinical presentations. Blood 2001;97(1):81-88.

(36) Mostoslavsky G, Fischel R, Yachimovich N, Yarkoni Y, Rosenmann E, Monestier M, et al. Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: A case for tissue injury by molecular mimicry. Eur J Immunol 2001;31(4):1221-1227.

(37) Caplan S, Baniyash M. Searching for significance in TCR-cytoskeleton interactions. Immunol Today 2000;21(5):223-228.

(38) Bronstein-Sitton N, Wang L, Cohen L, Baniyash M. Expression of the T cell antigen ζ receptor chain following activation is controlled at distinct checkpoints. Implications for cell surface receptor down-modulation and re-expression. J Biol Chem 1999;274(33):23659-23665.

(39) Bishara A, Aker M, Amar A, Brautbar C, Schlesinger M, Rabinowitz R, et al. Enhanced lymphoid cell recovery after bone marrow transplantation: Correlation with the presence of costimulatory antibodies in serum. Exp Hematol 1998;26(7):580-587.

(40) Avni O, Pur Z, Yefenof E, Baniyash M. Complement receptor 3 of macrophages is associated with galectin-1-like protein. J Immunol 1998;160(12):6151-6158.

(41) Palumbo GA, Yarom N, Gazit A, Sandalon Z, Baniyash M, Kleinberger-Doron N, et al. The tyrphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2. Cancer Res 1997;57(12):2434-2434.

(42) Caplan S, Baniyash M. Normal T cells express two T cell antigen receptor populations, one of which is linked to the cytoskeleton via ζ chain and displays a unique activation-dependent phosphorylation pattern. J Biol Chem 1996;271(34):20705-20712.

(43) Wang L, Bronstein N, Hsu V, Baniyash M. Transcriptional regulation of the murine TCR ζ gene. Int Immunol 1995;7(10):1627-1635.

(44) Caplan S, Baniyash M. Multisubunit receptors in the immune system and their association with the cytoskeleton: In search of functional significance. Immunol Res 1995;14(2):98-118.

(45) Caplan S, Zeliger S, Wang L, Baniyash M. Cell-surface-expressed T-cell antigen-receptor ζ chain is associated with the cytoskeleton. Proc Natl Acad Sci U S A 1995;92(11):4768-4772.

(46) Messika EJ, Avni O, Gallily R, Yefenof E, Baniyash M. Identification and characterization of a novel protein associated with macrophage complement receptor 3. J Immunol 1995;154(12):6563-6570.

(47) Hsu VW, Klausner RD, Fine JS, Kruisbeek AM, Baniyash M. Changes in the methylation pattern of the TCR zeta-chain gene correlate with its expression in T cells and developing thymocytes. New Biol 1992;4(2):166-171.

(48) Baniyash M, Hsu VW, Seldin MF, Klausner RD. The isolation and characterization of the murine T cell antigen receptor ζ chain gene. J Biol Chem 1989;264(22):13252-13257.

(49) Klausner RD, Weissman AM, Baniyash M, Bonifacino JS, Samelson LE. The role of the zeta chain in the expression, structure and function of the T cell receptor. Adv Exp Med Biol 1989;254:21-24.

(50) Baniyash M, Garcia-Morales P, Luong E, Samelson LE, Klausner RD. The T cell antigen receptor ζ chain is tyrosine phosphorylated upon activation. J Biol Chem 1988;263(34):18225-18230.

(51) Weissman AM, Baniyash M, Hou D, Samelson LE, Burgess WH, Klausner RD. Molecular cloning of the zeta chain of the T cell antigen receptor. Science 1988;239(4843):1018-1021.

(52) Baniyash M, Kehry M, Eshhar Z. Anti-IgE monoclonal antibodies directed at the Fcϵ receptor binding site. Mol Immunol 1988;25(8):705-711.

(53) Sharon M, Gnarra JR, Baniyash M, Leonard WJ. Possible association between IL-2 receptors and class I HLA molecules on T cells. J Immunol 1988;141(10):3512-3515.

(54) Baniyash M, Garcia-Morales P, Bonafacino JS, Samelson LE, Klausner RD. Disulfide linkage of the ζ and η chains of the T cell receptor. Possible identification of two structural classes of receptors. J Biol Chem 1988;263(20):9874-9878.

(55) Baniyash M, Eshhar Z. Anti‐anti‐IgE idiotypic antibodies mimic IgE in their binding to the Fcϵ receptor. Eur J Immunol 1987;17(9):1337-1342.

(56) Baniyash M, Alkalay I, Eshhar Z. Monoclonal antibodies specific to the α-subunit of the mast cell's Fc(ε)R block IgE binding and trigger histamine release. J Immunol 1987;138(9):2999-3004.

(57) Baniyash M, Eshhar Z, Rivnay B. Relationships between epitopes on IgE recognized by defined monoclonal antibodies and by the Fc(ε) receptor on basophils. J Immunol 1986;136(2):588-593.

(58) Baniyash M, Eshhar Z. Inhibition of IgE binding to mast cells and basophils by monoclonal antibodies to murine IgE. Eur J Immunol 1984;14(9):799-807.

(59) Baniyash M, Smorodinsky NI, Yaakubovicz M, Witz IP. Serologically detectable MHC and tumor-associated antigens on B16 melanoma variants and humoral immunity in mice bearing these tumors. J Immunol 1982;129(3):1318-1323.

(60) Baniyash M, Netanel T, Witz IP. Differences in Cell Density Associated with Differences in Lung-colonizing Ability of B16 Melanoma Cells. Cancer Res 1981;41(2):433-437.